Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Sees Large Drop in Short Interest

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) was the recipient of a significant decline in short interest in June. As of June 30th, there was short interest totaling 6,372 shares, a decline of 35.7% from the June 15th total of 9,904 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 8,436 shares, the short-interest ratio is presently 0.8 days.

Cryo-Cell International Stock Down 0.6%

Cryo-Cell International stock opened at $3.46 on Friday. The firm has a market cap of $27.89 million, a PE ratio of -11.53 and a beta of 0.49. Cryo-Cell International has a 52-week low of $2.72 and a 52-week high of $5.43. The company’s 50 day moving average is $3.52 and its two-hundred day moving average is $3.45.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $0.07 EPS for the quarter. The business had revenue of $7.78 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is owned by institutional investors and hedge funds.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.